Sponsors (10)
The bill increases research coordination, trial readiness, and public awareness that could accelerate progress for glioblastoma patients and support researchers, but it raises costs (to patients and the federal budget) and could create unrealistic near‑term expectations.
Patients with glioblastoma (and the clinicians who treat them) could see faster progress toward new treatments because the bill increases research funding, coordination across institutions, and trial readiness.
Patients, families, and caregivers could benefit from greater public awareness leading to earlier diagnosis, better caregiver support, and reduced delays in care.
Researchers and medical institutions could gain improved multi‑institutional collaboration and emphasis on biomarker testing, improving trial design, diagnostic accuracy, and future research capacity.
Patients could face higher out‑of‑pocket costs if expanded emphasis on biomarker testing is not covered by insurers, increasing the financial burden on those with glioblastoma.
Federal spending would increase to support expanded research and clinical programs, potentially requiring higher taxes or diverting funds from other programs that taxpayers rely on.
Greater public attention and emphasis on research may raise expectations for near‑term treatment breakthroughs that are unlikely given glioblastoma's historical resistance to therapy, risking disappointment and emotional harm for patients and families.
Based on analysis of 2 sections of legislative text.
Records findings on glioblastoma incidence, survival, costs, diagnostic gaps, and research needs; urges increased awareness and research support.
Official title: Designating July 16, 2025, as "Glioblastoma Awareness Day".
Introduced June 17, 2025 by Lindsey O. Graham · Last progress June 17, 2025
States findings about glioblastoma — including incidence, survival, diagnostic challenges, treatment approvals, patient financial burden, and the National Cancer Institute’s Glioblastoma Therapeutics Network — and calls for greater public awareness and patient/caregiver involvement in research. The resolution documents gaps in screening, limited FDA-approved therapies, and the need to support research and early‑phase clinical efforts.